newsfilter
← Latest News
Business Wire·

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative